Agreements reached under this partnership
Business alliance (license agreement)- 1
GEI will obtain a license to the NMN-producing strain and production process technology developed by SynArt.
- 2
The parties will promote the realization of commercial production by utilizing GEI’s expertise in optimizing and scaling up fermentation-based manufacturing processes.
- 3
The parties aim to begin OEM production in 2027.
- 4
The parties plan to sell NMN on a several-ton scale in 2030.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The parties aim to begin OEM production in 2027 and plan to sell NMN on a several-ton scale in 2030.
| Item | Details |
|---|---|
| Name of alliance partner | SynArt |
| Alliance partner's business activities | Domestic biotechnology manufacturing company |
| Type of alliance | Business alliance (license agreement) |
| Details of the alliance | GEI will obtain a license to the NMN-producing strain and production process technology developed by SynArt., The parties will promote the realization of commercial production by utilizing GEI’s expertise in optimizing and scaling up fermentation-based manufacturing processes., The parties aim to begin OEM production in 2027., The parties plan to sell NMN on a several-ton scale in 2030. |
| Numerical targets under the alliance | The parties aim to begin OEM production in 2027 and plan to sell NMN on a several-ton scale in 2030. |
| Contract Date | 16 April 2026 |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To provide a stable supply of NMN suitable for food applications by combining SynArt’s strain and production technology with GEI’s expertise in optimizing and scaling up fermentation-based manufacturing processes, against a backdrop of growing demand for NMN.